

Science & Research

INHIBITORS OF ANGIOGENESIS IN BRAIN TUMORS – REVIEW

Mindov I., Petrov B., Atsev S., Valkanov S.

Neurosurgical department, UMHAT „Prof. Dr. Stoyan Kirkovich” JSC, Bulgaria

Introduction

Malignant glial and metastatic tumors are highly vascularized tumors and like all solid tumors, they require angiogenesis for their growth. [1] For glioblastoma (GBM) this microvascularization is very likely and those vessels have abnormal structure, shape and organization.[2] The permeability of those blood vessels is high and very variable in space and time.[3, 4] This abnormal permeability and aberrant morphologic vascular network are associated with abnormal - blood flow, oxygen and nutrients delivery, and also decreased delivery of applied systemic medications.[5] The microenvironment of the tumor has zones of hypoxia, interstitial hypertension and necrosis.[6, 7, 8, 9, 10] According to *Hobbs et al.*, when the tumor diameter reaches 1-2mm, the integrity of blood brain barrier (BBB) is structurally and functionally impaired. The abnormal permeability and efflux can be visualized on MRI/CT scan imaging as enhancement of the contrast.

Materials and methods

We gathered published materials related to mechanisms of action of VEGF inhibitors and especially in brain tumors, including data from the past decade. Also, according to the literature we defined the most applicable agents in VEGF targeted therapy. Their advantages and disadvantages, probable benefit, also according to the gathered literature. (Fig. 1)

Mechanisms of action of VEGF inhibitors

Glioblastomas use several mechanisms of forming new blood vessels. (**Fig.1**) Initially the tumor growth could appear as a “co-option” of already existed, natural blood vessels. Malignant cells - they can migrate by using already existed healthy blood vessels and can structurally destabilize them. This leads to regression of those vessels and reduction of blood flow and local hypoxia. [11] As a result – the local hypoxia stimulates the secretion of proangiogenic cytokines. [11, 12] The new vascular network can be formed by angiogenesis, where the progenitor cells derived from stem cells, penetrate in the circulation and are incorporated directly. [14]

Multiple complex and alternative molecular pathways are involved in growth and development of the new vascular web. Since there are a lot of pathways and details related to brain tumor angiogenesis, we will focus only on VEGF signaling transduction pathway. GBMs produce several pro-angiogenic factors, including VEGF [15], PDGF-b[16], HGF/SF[17,18] and bFGF [19]. VEGF-A (also known as VEGF) is one of the key regulators of the tumor angiogenesis – the signaling transduction pathway of which, starts with binding of VEGF to VEGFR-2, that is mostly a membrane receptor mainly on the surface of the endothelial cells.[20, 21] The expression of VEGF can be increased by several factors. The hypoxic environment, increases the expression and stabilization of heterodimer transcriptional factor HIF-1b – a key

mediator synthesized in response to hypoxia, which leads to increased transcription of many genes involved in survival of the cell and the angiogenesis itself, including VEGF.[22] High levels of HIF-1 β and VEGF are associated with higher malignancy grade.[15, 23] The expression of VEGF is also increased by nitric oxide (NO), acidosis, other growth factors, loss of tumor suppressor genes (e.g. **p53**) and activation of oncogenes (e.g. **v-src**).[20, 24, 25]

Binding of VEGF to VEGFR-2 leads to dimerization of the receptor which is associated with tyrosine kinase(RTK), trans-autophosphorylation of the receptor and activation of several intracellular enzymes (protein-kinases) and the result of that cascade is endothelial proliferation, migration and survival. These pathways involve *mitogen-activated protein kinase* (MAPK) and *phosphatidylinositol-3'-kinase* (PI3K)-Akt.[20, 26] VEGF also increases the expression of *Delta-like ligand 4* (Dll4).The (Notch) Dll signaling pathway is an important stimulator of angiogenesis and there are a lot of studies that are still running, because it can be used as a potential therapeutic target.[20] The inhibition of Dll4 leads to unproductive angiogenesis which leads to decreased perfusion, increased hypoxia and decreased tumor growth.[27, 28]

Furthermore VEGF interacts with *angiopoietin signaling pathway*.*Angiopoethin-1* (**ang-1**) and *Angiopoethin-2* (**ang-2**), a couple - agonist/antagonist with significant homologous sequence, are the main ligands, which connect and mediate the signalization through **Tie-2** – tyrosine kinase receptor expressed over the endothelial cells.[29] In the presence of VEGF, the binding of ang-2 to Tie-2, stimulates angiogenesis.[30] Future investigations related to detailed studying of these pathways may be helpful for developing new therapeutic agents.

Inhibitor mechanisms of VEGF in brain tumors.

Anti-VEGF mechanisms are not fully understood and there are several hypotheses. Classically it is considered, that VEGF inhibitors prevent developing of new vessels, which will lead to low levels of oxygen and nutrients, needed for the tumor's growth. [31] Second potential mechanism of action VEGF inhibitors, is that there is vascular's wall normalization, according to which leads to reduction of undeveloped vessels and stabilization by perivascular cells and basal membrane. [32, 33] Thus will lead to increased delivery of concurrent chemotherapeutics and increased response to radio therapy. [32, 33]

VEGF inhibitors interrupt the interaction between the endothelial cells and “stem-like cells” of GBM, as well as perivascular-stem cell niche distortion, which may contribute to the death of these stem cells. [35, 36] Many anti-angiogenic agents, based on these mechanisms are being in a process of investigation for the treatment of brain tumors. (Fig. 2)

VEGF Antibodies

Bevacizumab

Bevacizumab is recombinant antibody, which neutralizes all isoforms of human VEGF.33 years after the first conception of angiogenesis of Dr. J. Folkman, Bevacizumab becomes the first developed inhibitor of angiogenesis, which is approved by FDA. [20] Some investigations show that bevacizumab may have activity against recurrent malignant gliomas. In series of patients with recurrent malignant gliomas, who are treated in a combination with

bevacizumab and conventional chemo- and radiotherapy there is 27-66% response to that therapy. [37, 38, 39, 40]. At this moment bevacizumab is approved as a drug for the treatment of recurrent glioblastomas. Many investigations are being taken to evaluate the efficacy of bevacizumab in combination with other drugs in patients with recurrent and also newly diagnosed with GBMs. [41]

VEGF ‘decoys’

Aflibercept is fusive protein, composed of extracellular domeins of the VEGF-receptors 1 and 2, connected with the Fc-part of IgG1, and produced in K1 cells of Chinese hamster’s ovary (CHO) through recombinant DNA technology, which mostly is studied in pre-clinical trials. Aflibercept acts as a receptor-decoy, which binds VEGF-A and PlGF, and thereby inhibits binding and activation of VEGF-receptors. [42]

Tyrosine-kinase inhibitors

Cediranib

Cediranib (Recentin) is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors, and additionally acts against c-Kit and PDGF receptors. [43] The preclinical profile of Cediranib indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor. Phase I data indicate that Cediranib is generally well tolerated, with the most common dose related adverse events being diarrhoea, hoarseness, headache and hypertension.

Cediranib inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK). By forming a blockade at the VEGF receptors, Cediranib limits the growth of new blood vessels, which are essential to supporting tumor growth. Thus, lacking sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth and potentially improving the efficacy of other treatments. Preclinical evidence indicated that the drug had a high affinity at these sites, and was well tolerated and efficacious in animal studies. Future studies of the effect of the agent in combination with other agents, in treatment of recurrent glioblastomas, are yet to be done. [43]

Valatinib

Valatinib (PTK787) is an oral pan-VEGF,c-kit and PDGFR tyrosine kinase inhibitor, which is studied for treatment of newly diagnosed and recurrent malignant gliomas.[44] At this moment this agent is rejected, despite the results that are obtained from these studies.

Other Tyrosine Kinase Inhibitors

Sorafenib

Sofarenib (Nexavar) is a multitarget kinase inhibitor with action against a lot of kinase enzymes, including VEGFR, PDGFR, c-Kit, Ret and Raf. [45] Sorafenib has antiproliferative effect (in vitro) against cell lines of malignant gliomas. [46] At this stage of the studies related to this medication, there are good results in patients with recurrent malignant gliomas.

Investigations in combination with other VEGF inhibitors including **sunitinib** and **vandetanib** are still processing. [47]

Immunomodulatory Agents

Thalidomide & Lenalidomide

There are a lot of investigations for potential anti-angiogenic therapies in different cancers including primary and secondary. Some of this therapies include direct inhibitors tyrosine-kinases (eg. sorafenib), direct inhibitors of tyrosine kinase receptors (eg. VEGFR, EGFR, PDGFR) [48, 49] and other therapies that include immunomodulatory agents such as Thalidomide and Lenalidomide. Mechanisms of immunomodulatory agents: The Inhibition of TNF (tumor necrosis factor) [50] is thought to be the immunomodulatory effect of thalidomide, but not its anti-angiogenic activity's mechanism. The inhibition of tumors angiogenesis is unclear, but is possibly due to the inhibition of VEGF and bFGF. [51, 52]

Thalidomide

There results of monotherapy with Thalidomide in recurrent glioblastoma patients are very poor – only 5-6% have responded to radiotherapy. [51, 53, 54] There are different results in combination therapies: For some of the combination therapies there was no evidence for better response, for example the combination of thalidomide and temozolomide (Temodar) had a small effect in recurrent primary glial tumors and the radiation therapy response was also very poor. [55, 56, 57] For other combinations there was evidence for better response. The combination of thalidomide with carmustine was associated with better radiographic response -24% in phase II trial .[58]

Lenalidomide (Revlimid,Celgene)

A thalidomide analog with greater anti-angiogenic activity. The monotherapy response to Lenalidomide was poor in patients with recurrent malignant gliomas. In phase I trial of newly diagnosed glioblastomas also there was no evidence of better response to radiotherapy in combination with lenalidomide. [59, 60]

Thalidomide was evaluated also for patients with metastatic brain tumors.

In a phase III study of thalidomide in patients with multiple brain metastases there was a study that compared whole brain radiotherapy in combination with thalidomide versus whole brain radiotherapy without thalidomide. There was no evidence for better response to the radiation therapy – both groups had median survival of 3.9 months.

A phase II study of thalidomide monotherapy in patients with brain metastases from melanoma showed limited activity. [61]

The combination of thalidomide, temozolomide and whole-brain radiation therapy to patients with brain metastases from melanoma also showed little efficacy. [62]

There will be future studies of thalidomide and lenalidomide in malignant gliomas and also in metastatic brain tumors.

Discussion

Although there is a proved benefit in application of anti-angiogenic agents, most patients experience at some point tumor progression. Tumor develop resistance to angiogenic inhibitors. [63] Mechanisms of resistance include - turning alternative pro-angiogenic pathways, protection of tumor vascular system, and ability to invade, without angiogenesis. [63] Further researches are needed to study the all the mechanisms of tumors' to develop resistance to anti-angiogenic therapy.

Conclusion

Angiogenesis is not fully understood and all its molecular pathways. The researches and trials done by now, including monotherapeutic or combined-one approach, show that anti-angiogenic agents show efficacy in the treatment of malignant primary and secondary brain tumors. The prolonged progression free period, as well as the lesser vasogenic edema, are proved to be related with application of anti-angiogenic agents. The need of more prospective trials - to validate the up-to-date results and to investigate the other targets of pro-angiogenic pathways.

Regardless the application of anti-angiogenic drugs in primary and secondary brain tumors shows to be a promising therapeutic approach, which has the potential to have a significant impact in the treatment of brain oncologic patients. [64]

References

1. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. *J Natl Cancer Inst.* 1972;48:347-356.
2. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. *J Neurooncol.* 2006;78:281-293
3. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. *Nat Rev Neurosci.* 2007;8:610-622
4. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A.* 1998;95:4607-4612
5. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. *Cancer Res.* 2007;67:2729-2735.
6. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO₂ gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med.* 1997;3:177-182
7. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinoma transplanted in rat and mouse cranial windows. *Cancer Res.* 1994;54:4564-4568
8. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. *Cancer Res.* 1996;56:4264-4266.

9. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO₂ distribution and bioreductive enzymes in human malignant brain tumors. *Int J Radiat Oncol Biol Phys.* 1994;29:427-43
10. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. *J Neuropathol Exp Neurol.* 2006;65:529-53
11. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science.* 1999;284:1994-1998
12. Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. *Lab Invest.* 2000;80:837-849.
13. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. *Nature.* 2000;407:242-248
14. Duda DG, Cohen KS, Kozin SV, et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. *Blood.* 2006; 107:2774-2776
15. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. *Nature.* 1992;359:845-848
16. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. *J Neurosurg.* 1995; 82:864-873.
17. Schmidt NO, Westphal M, Hagemel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. *Int J Cancer.* 1999; 84:10-18.
18. Abounader R, Lattera J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. *Neuro Oncol.* 2005; 7:436-451.
19. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. *Cancer Res.* 1991; 51:5760-5765.
20. Kerbel RS. Tumor angiogenesis. *N Engl J Med.* 2008;358:2039-2049.
21. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. *Nature.* 1994;367: 576-579.
22. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. *Neuro Oncol.* 2005; 7:134-153
23. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. *J Neurooncol.* 2006; 78:233-247.
24. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. *Nat Rev Cancer.* 2006; 6:521-534.
25. Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. *Oncogene.* 1997; 14:2005-2013
26. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. *Exp Cell Res.* 2006; 312:549-560.
27. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. *Nature.* 2006; 444:1083-1087.
28. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. *Nature.* 2006; 444:1032-1037
29. Hanahan D. Signaling vascular morphogenesis and maintenance. *Science.* 1997;277:48-50

30. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. *Cancer Cell*. 2004;6:507-516
31. Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov*. 2007;6:273-286
32. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell*. 2004;6:553-563
33. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. *Cancer Res*. 2004;64:3731-3736
34. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell*. 2007;11:83-95.
35. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. *Cancer Cell*. 2007;11:69-82.
36. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. *Cancer Res*. 2006;66:7843-7848.
37. Stark-Vance V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. *Neuro Oncol*. 2005;7:369.
38. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology*. 2008;70:779-787.
39. Guiu S, Taillibert S, Chinot O, et al. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. *Rev Neurol (Paris)*. 2008;164:588-594.
40. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. *Neurology*. 2006;66:1258-1260.
41. Brastianos PK, Batchelor TT. VEGF inhibitors in Brain tumors, *Clinical Advances in Hematology & Oncology* Volume 7, Issue 11, November 2009, p.755-756
42. European Medicines Agency, Science medicines health EMA, EPAR Summary for the public/751145/2015 EMEA/H/C/002392
43. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell*. 2007;11:83-95
44. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. *Neurosurgery*. 2004;55(2):426-432; discussion 432
45. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer Res*. 2006;66:11851-11858.
46. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. *J Pharmacol Exp Ther*. 2006;319:1070-1080.
47. Nabors L, Rosenfeld M, Chamberlain M, et al. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). *J Clin Oncol (ASCO Annual Meeting Abstracts)*. 2007;25(June 20 Supplement):Abstract 2058

48. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A*. 1994;91:4082-4085.
49. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. *Anticancer Drugs*. 1996;7:339-343.
50. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. *Mol Med*. 1995;1:384-397.
51. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. *J Neurooncol*. 2001;54:31-38.
52. Puduvalli VK, Giglio P, Groves MD, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. *Neuro Oncol*. 2008;10:216-222.
53. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. *J Neurooncol*. 2001;51:41-45.
54. Fine HA, Figg WD, Jaecle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. *J Clin Oncol*. 2000;18:708-715.
55. Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. *J Neurooncol*. 2007;81:271-277.
56. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. 2004;60:353-357.
57. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. *Neuro Oncol*. 2008;10:300-308.
58. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. *J Clin Oncol*. 2003;21:2299-2304.
59. Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. 2009;73:222-227.
60. Fine HA, Kim L, Albert PS, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. *Clin Cancer Res*. 2007;13:7101-7106.
61. Vestermarck LW, Larsen S, Lindelov B, Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. *Acta Oncol*. 2008;47:1526-1530.
62. Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. *Cancer*. 2008;113:2139-2145.
63. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer*. 2008;8:592-603.
64. Brastianos K.P., Batchelor T.T. et al, VEGF Inhibitors in Brain Tumors, *Clinical Advances in Hematology & Oncology* Volume 7, Issue 11 November 2009, 753-768




Fig.1 Schematic representation of different mechanisms of new blood vessel formation. A) Blood vessels are composed of astrocytes, pericytes, and endothelial cells. B) Tumor cells infiltrate along blood vessels. C) As the tumor grows, it co-opts normal capillaries using various cytokines. D) Blood vessels are compressed and destabilized, which decreases perfusion, and results in hypoxia. Hypoxic conditions result in increased secretion of several growth factors such as vascular endothelial growth factor (VEGF), stromal-cell-derived factor (SDF-1), basic fibroblast growth factor (bFGF), and Interleukin 8 (IL8). E) Bone-marrow-derived (BMD) cells and SDF-1 are recruited to induce vasculogenesis. Reprinted from Jain et al. Angiogenesis in brain tumours. *Nat Rev Neurosci.* 2007;8:610-622.




Figure 2. Schematic representation of mechanisms of anti-angiogenic treatment. A) Healthy tissues have balanced signaling from pro- and anti-angiogenic factors, and this results in an organized, effective vasculature. B) Tumors produce anti-angiogenic factors, which create a highly disorganized vascular network. C) Anti-angiogenic therapy can normalize the vasculature and allows for more effective delivery of drug. D) With potent anti-angiogenesis, the tumor is starved of nutrients and oxygen, with resulting necrosis of tumor.

IFP=interstitial fluid pressure; pO_2 =tissue oxygen level

Reprinted from Jain et al. Angiogenesis in brain tumours. *Nat Rev Neurosci.* 2007;8:610-622.